TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25771759
Drug: Forearm tourniquet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forearm tourniquet IVRA with 10 mL of 0.5% lidocaine and 30 mL of 0.25% lidocaine
Study: 25771759
Drug: Conventional upper
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional upper arm tourniquet IVRA with 40 mL of 0.5% lidocaine
Study: 24210183
Drug: Pre-operative chemotherapy
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative chemotherapy followed by delayed nephrectomy
Study: 11324215
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded single-tooth implants in fresh extraction sites
Study: 11324215
Drug: Immediately loaded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediately loaded single-tooth implants in healed sites
Study: 28600913
Drug: Once-daily SMBG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily SMBG
Study: 28600913
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (including no SMBG, once-daily SMBG, and once-daily SMBG with messaging)
Study: 23589107
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with HLA-A*0201-modified tumor peptides and low-dose cyclophosphamide (CTX) and low-dose interleukin-2 (IL-2)
Study: 16469146
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk with L. johnsonii La1
Study: 16469146
Drug: Placebo (fermented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (fermented milk without L. johnsonii La1)
Study: 9140210
Drug: Vanadyl sulphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vanadyl sulphate treatment group
Study: 25854021
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) combined with ultraviolet therapy
Study: 25854021
Drug: Medicine group
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine group (intravenous acyclovir, muscular cobamamide, topical acyclovir, TDP radiation)
Study: 17429101
Drug: No Gap
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Gap (immediate treatment)
Study: 15552889
Drug: Protease inhibitors,
Normalized name: Protease inhibitors, direct acting antivirals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitors, H2 receptor antagonists, and somatostatin analogues
Study: 24802242
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (2 NRTI plus protease inhibitor)
Study: 6092990
Drug: Methylprednisolone (45‐60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (45‐60 mg/M2)
Study: 31498137
Drug: Constraint-Induced Movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-Induced Movement Therapy (CIMT) - less affected limb blocked by a splint
Study: 24228803
Drug: DHA (500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (500mg daily)
Study: 24228803
Drug: DHA plus
Normalized name: PNV-DHA Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA plus EPA mixture (500mg daily)
Study: 16080791
Drug: Lactobacillus fermentum
Normalized name: Lactobacillus Fermentum
DrugBank: Lactobacillus fermentum (DB16542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus fermentum ME‐3 in fermented goat milk (daily dose 11.8 log CFU)
Study: 16080791
Drug: Lactobacillus fermentum
Normalized name: Lactobacillus Fermentum
DrugBank: Lactobacillus fermentum (DB16542)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus fermentum ME‐3 in capsules (daily dose 9.2 CFU)
Study: 7995059
Drug: Second pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second pulse therapy (at 24h and 48h)
Study: 1695053
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMW heparin)
Study: 2838681
Drug: Standard unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard unfractionated heparin (UF heparin)
Study: 14605030
Drug: Abrupt discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt discontinuation of nitrate treatment (study group)
Study: 3890700
Drug: Mesulergine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesulergine 20 mg daily
Study: 20454927
Drug: Ixabepilone plus
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone plus capecitabine (40 mg/m² intravenously on day 1 of a 21-day cycle plus 2,000 mg/m² orally on days 1-14 of a 21-day cycle)
Study: 20454927
Drug: Capecitabine alone
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine alone (2,500 mg/m² on the same schedule)
Study: 15900423
Drug: External-beam irradiation
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External-beam irradiation administered as a 40-Gy dose under normal oxygenation conditions
Study: 15900423
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose under normoxic conditions
Study: 31467066
Drug: Long-acting G-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting G-CSF for all chemotherapy cycles
Study: 27932353
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg/d) + Statin (E+S)
Study: 27932353
Drug: Statin Monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin Monotherapy (S)
Study: 23606983
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 mg at bed time)
Study: 26578849
Drug: Dabigatran 220
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 220 mg once daily
Study: 19923527
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg IV before incision, 24-h infusion at 2 microg x kg(‐1) x min(‐1))
Study: 19923527
Drug: Placebo (blinded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (blinded saline bolus and infusion)
Study: 17352522
Drug: Clopidogrel added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel added to aspirin therapy
Study: 11563412
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg with sertraline 50 mg
Study: 1782951
Drug: alteplase 100
Normalized name: alteplase 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: alteplase 100 mg in 3 h
Study: 27893045
Drug: Chlorthalidone (thiazide-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (thiazide-type diuretic)
Study: 25087908
Drug: Oxytocin nasal
Normalized name: oxytocin Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin nasal spray (18 or 24 International Units), administered twice-daily for 8 weeks
Study: 25087908
Drug: Placebo nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray, administered twice-daily for 8 weeks
Study: 19265481
Drug: Control subjects
Normalized name: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control subjects (first dose of vaccine)
Study: 9552772
Drug: 2-Chloroprocaine (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-Chloroprocaine (90 mg)
Study: 8022626
Drug: Bupivacaine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (25 mg)
Study: 9552772
Drug: 2-Chloroprocaine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-Chloroprocaine (60 mg)
Study: 15671224
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron (125 mg FeSO4, 10 microg folate, 25 mg vitamin C)
Study: 15671224
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 microg folate and 25 mg vitamin C)
Study: 8932539
Drug: AC137 30-mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC137 30-mug infusion dose
Study: 8932539
Drug: AC137 300-mug
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC137 300-mug infusion dose
Study: 1763292
Drug: Budesonide 1
Normalized name: BUDESONIDE 1MG/2ML SUSP,INH,2ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 1 mg/100 ml
Study: 1763292
Drug: Budesonide 2
Normalized name: budesonide 2 MG/ACTUAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 2 mg/100 ml
Study: 26979470
Drug: Daily physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily physical activities (DA)
Study: 23216943
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with etanercept and standardized HRQoL assessment and communication
Study: 23216943
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with etanercept alone
Study: 20973707
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system (MTS) 10-30 mg/9 hours
Study: 20492851
Drug: Placebo transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo transdermal system (PTS)
Study: 12492613
Drug: Quinine sulphate
Normalized name: Quinine sulphate
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine sulphate (600 mg) alone
Study: 12492613
Drug: Quinine sulphate
Normalized name: Quinine sulphate
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine sulphate (600 mg) plus troleandomycin (TAO; 500 mg every 8 h)
Study: 9475328
Drug: Albuterol (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (180 microg b.i.d.)
Study: 30766
Drug: Lorazepam (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (3 mg/day: 2 mg in the evening and 1 mg in the morning)
Study: 31514233
Drug: Prednisone (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (0.4 mg/kg/d for 15 days, then 0.2 mg/kg/d for 15 days)
Study: 29251976
Drug: 15.8 mg/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15.8 mg/g Spectrum cigarette
Study: 29251976
Drug: 5.2 mg/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.2 mg/g Spectrum cigarette
Study: 29251976
Drug: 2.4 mg/g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 mg/g Spectrum cigarette
Study: 24067879
Drug: Telbivudine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine (600 mg/d)
Study: 26236924
Drug: Entecavir (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir (0.5 mg/d)
Study: 16998208
Drug: Physician's treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's treatment (control)
Study: 11740759
Drug: Fixed minidose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed minidose warfarin (2 mg daily)
Study: 8453847
Drug: Ciprofloxacin alone
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin alone (750 mg)
Study: 25229980
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.5 mg · kg(‐1) OM)
Study: 25229980
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine (2 μg · kg(‐1) IND)
Study: 25229980
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral honey and intranasal saline)
Study: 16431379
Drug: Atenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 50 mg (two pills)
Study: 12845759
Drug: Cisapride 5
Normalized name: cisapride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 5 mg three times a day
Study: 12845759
Drug: Cisapride 10
Normalized name: cisapride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 10 mg three times a day
Study: 9216948
Drug: Saline inhalation
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline inhalation (Control)
Study: 29178746
Drug: Power toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Power toothbrush (Oral-B Professional Care 7000)
Study: 23688422
Drug: 1000 μg
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 μg fluticasone propionate (FP)
Study: 14649610
Drug: Midazolam alone
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam alone (Group A: 1 mg/kg)
Study: 14649610
Drug: Midazolam plus
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam plus meperidine (Group B: 0.5 and 1 mg/kg)
Study: 8774204
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous heparin protocol
Study: 25147364
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine (0.1 mg/kg)
Study: 29762444
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma injection
Study: 16144892
Drug: Rosiglitazone, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone, 8 g/d
Study: 12696778
Drug: Oral oxybutynin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxybutynin 5 mg t.i.d. (Group II)
Study: 2197335
Drug: Avian-human influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avian-human influenza A/Bethesda/85 (H3N2) reassortant virus vaccine (10(3)-10(7) TCID50)
Study: 2197335
Drug: Cold-adapted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted influenza A/Bethesda/85 (H3N2) reassortant virus vaccine (10(3)-10(7) TCID50)
Study: 7423160
Drug: 3 daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 daily doses of 220 mg zinc sulfate (group B)
Study: 7423160
Drug: No zinc
Normalized name: ZINC OXIDE 140 mg in 1 mL TOPICAL CREAM [Lucin Organics Tinted Sunscreen SPF 30 Non Nano Zinc Oxide]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No zinc therapy (group A)
Study: 30819765
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy + temozolomide
Study: 28039050
Drug: HCG administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCG administration (250 IU intramuscularly 3 times per week for 4 weeks)
Study: 28039050
Drug: HCG administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCG administration
Study: 23566033
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose (group A)
Study: 9226739
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg idazoxan
Study: 10365924
Drug: Finasteride 1
Normalized name: finasteride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 1 mg/day
Study: 3317958
Drug: Lugol's iodine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lugol's iodine, 0.3 ml thrice daily for 9 days
Study: 24016490
Drug: Aleglitazar 150
Normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleglitazar 150 μg daily in addition to standard medical therapy
Study: 26678626
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily in addition to standard medical therapy
Study: 26093872
Drug: Aleglitazar 150
Normalized name: Aleglitazar
DrugBank: Aleglitazar (DB08915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleglitazar 150 μg daily
Study: 7626592
Drug: Psyllium and
Normalized name: Psyllium and senna only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psyllium and psyllium-citrus pectin mixture (2.2 g)
Study: 1782972
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl 75 micrograms/h (Fentanyl‐TTS)
Study: 7075190
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Sulprostone at 4 hourly intervals for 8 doses
Study: 31058986
Drug: Spray 1
Normalized name: FLUORI-METHANE TOP SPRAY 120ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray 1
Study: 23482590
Drug: DAG (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAG (4 μg/kg per h) infused over 210 min
Study: 23592479
Drug: Ghrelin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin administration
Study: 11352778
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum (125 ml, tds) co-administered with indomethacin (50 mg, tds)
Study: 11352778
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg, tds) with whey protein (control)
Study: 11352778
Drug: Colostral solutions
Normalized name: COLOSTRUM
DrugBank: Human colostrum (DB19286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colostral solutions (125 ml, tds)
Study: 11352778
Drug: Control solutions
Normalized name: Accu-Chek Comfort Curve Control Solutions
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solutions (125 ml, tds)
Study: 9209895
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metoclopramide (MTC) intravenous bolus after a 2-h saline infusion
Study: 9209895
Drug: 4-h dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-h dopamine infusion at 0.01 microgram/kg/min with a 10 mg intravenous bolus of MTC given at the second hour of dopamine infusion
Study: 9209895
Drug: 4-h saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-h saline infusion
Study: 2048592
Drug: 35 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 micrograms ethinyl estradiol and 0.5 mg norethindrone
Study: 3610737
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms mestranol and 1.0 mg norethindrone
Study: 28296201
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with lixisenatide and basal insulin (LIX group)
Study: 28296201
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily insulin injection therapy (MDI group)
Study: 29300991
Drug: Insulin-induced hypoglycemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-induced hypoglycemia
Study: 93043
Drug: tocainide (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: tocainide (400 or 600 mg every eight hours)
Study: 26076171
Drug: Morphine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (40 mg immediate release tablet)
Study: 20500802
Drug: Cerebrolysin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrolysin 60 ml
Study: 9674619
Drug: Mailed intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mailed intervention containing guidelines for the use of sedative hypnotics, a prescriber profile detailing sedative hypnotic prescribing, and a patient profile
Study: 7639342
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg d-alpha-tocopherol per day for 3 weeks
Study: 29691559
Drug: Hoshino's triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hoshino's triple antibiotic paste (Control)
Study: 14587651
Drug: Rilmenidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilmenidine (1 mg/day)
Study: 1910795
Drug: 360 ml
Normalized name: colostomy bags 10" 360 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 ml of apple juice, 150 mg of oral ranitidine (two doses), 10 mg of metoclopramide
Study: 1910795
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral fluids or acid aspiration prophylaxis
Study: 30489177
Drug: Tofacitinib low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tofacitinib low-dose (1 or 3 mg) with low-dose MTX
Study: 30489177
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg BID with low-dose MTX
Study: 30489177
Drug: Tofacitinib 10
Normalized name: tofacitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 10 mg BID with high-dose MTX
Study: 30489177
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with low-dose MTX
Study: 30489177
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with high-dose MTX
Study: 23565740
Drug: Vildagliptin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (50 mg twice daily)
Study: 8394849
Drug: Dalteparin sodium
Normalized name: Dalteparin Sodium
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin sodium (10,000 IU daily for weeks 1 and 2, 5,000 IU daily for weeks 3 and 4)
Study: 27391158
Drug: CRT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRT plus consolidation chemotherapy
Study: 24535848
Drug: Psychoeducation using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducation using a tablet PC during chemotherapy infusion (n=19)
Study: 18932271
Drug: Rasagiline (neuroprotective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline (neuroprotective therapy)
Study: 12870166
Drug: 20% Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% Intralipid infusion (0.4 mL(‐1) x kg(‐1) x h(‐1))
Study: 10420420
Drug: Three-dose emotional
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose emotional expression writing group
Study: 7194061
Drug: etofylline clofibrate
Normalized name: etofylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: etofylline clofibrate (3 x 250 mg)
Study: 7194061
Drug: standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard preparation (clofibrate 3 x 500 mg and beta-pyridylcarbinol hydrogentartrate 3 x 25 mg)
Study: 29768709
Drug: IMQ (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMQ (5 mg) applied once daily for 72 hours under occlusion to intact skin (n = 8)
Study: 26500351
Drug: Tafenoquine (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafenoquine (50, 100, 300, or 600 mg) plus chloroquine